Skip to main content
Premium Trial:

Request an Annual Quote

OncoMethylome to Provide Methylation Testing Services for Merck Study

NEW YORK (GenomeWeb News) – OncoMethylome Sciences said today that it will provide MGMT gene promoter methylation testing services for Merck KGaA’s clinical trial program for cilengitide, a drug being developed for glioblastoma multiforme treatment.
 
As part of the agreement, Germany’s Merck also gained a worldwide, non-exclusive license to use the results from the methylation assay for optimizing cilengitide treatment.
 
Liege, Belgium-based OncoMethylome said that its MGMT assay is based on studies that showed methylation of the MGMT gene promoter may help to identify brain tumors that are more likely to respond to standard chemotherapeutic agents.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.